Sandoz invests € 50 million | INVEST in AUSTRIA

Sandoz is continuing to invest in its Austrian production facility in order to satisfy growing global demand for important antibiotics. The company is investing € 50 million in increasing production capacities for penicillin in a finished dosage form.

Penicillin is the world’s most common form of antibiotic. The new project comes on the heels of plans announced in the previous year to invest € 100 million in a modern production technology for producing oral amoxicillin active pharmaceutical ingredients in Kundl in Tyrol, Austria.

Automation, the most advanced technology for producing active pharmaceutical ingredients and an optimisation of processes will make it possible to integrate all production steps into a single process at one site. In turn, this will increase capacity and supply reliability. A new three-storey building will be constructed next to the existing penicillin production plant and will boast total floor space of 1,875 m². The new facility will be put into operation at the beginning of 2024.

Sandoz CEO Richard Saynor stated. “Antibiotics remain the backbone of modern medicine. We are currently seeing rapidly increasing demand following the unprecedented market swings of the past few years. This investment will help meet growing patient need, to support the creation of hundreds of new jobs and to partially offset the impact of high energy prices by lowering unit costs.” Sandoz, a division of Novartis, is a global market leader for generics and biosimilars and generated revenue of USD 9.6 billion in 2021.

Continue reading and find out more about Austria as a research location!

Takeover of TU Wien spin-off Cubicure by Align Technology confirms Austria's research spirit and attractiveness as a high-tech location

11. April 2024

Cubicure is a true pioneer in the development of advanced 3D printing systems which also enable the manufacturing of medical devices. The two founders - Robert Gmeiner and Jürgen Stampfl – explain how the successful spin-off Cubicure emerged in March 2015 from a research idea at the Vienna University of Technology and why Austria was the perfect location for establishing the company.

Austria’s Medical Technology Sector on the Upswing

11. April 2024

In an era featuring rapid technological progress, the medical technology industry in Austria has proven to be a key factor underlying innovation, economic growth, and social progress. Austria is a key player in the field of medical technology, reflected in groundbreaking developments in 3D printing and the country’s strong focus on exports.

World-class Research at the Medical University of Vienna

11. April 2024

The Medical University of Vienna conducts research at a world-class level in fields such as precision oncology and bionic reconstruction. Construction of the Eric Kandel Institute – Center for Precision Medicine and top spots in global rankings underline the university’s role as a pioneer in life sciences research.